Showing : 28–36 of 93
Dr. Shiu Ho memorial lectures, which HCRI supports each year in collaboration with the Division of Cardiology at the Beth Israel Deaconess Medical Center are now available for viewing.
The DAPT Score - a Decision Tool to Predict Benefit and Risk of Extended Duration Dual Antiplatelet Therapy.
HCRI’s Dr. Robert Yeh has recently been named as the Director of the Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center
HCRI's Chief Scientific Advisor, Dr. Laura Mauri will presenting at AHA :
The Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) study shows that Asthma exacerbations are not reduced in black adults when a long acting beta-agonist (LABA) is added to treatment with inhaled corticosteroids (ICS).
Harvard Clinical Research Institute has expanded its endpoint adjudication services - and significantly reduced the timeline to complete the process - by implementing eClinicalOS (eCOS).
Dr. Laura Mauri will be the morning keynote speaker at the Clinical Trial Innovation & Reform Workshop, taking place on April 29, 2015 in Washington, D.C. Dr. Mauri will be presenting “An Investigator’s Perspective on Medical Device Clinical Trial Innovation”.
The PINNACLE Registry is cardiology's largest outpatient quality improvement registry. It collects data about patients in participating cardiology practices to help providers evaluate and improve their adherence to current guidelines, and it provides a wealth of data for research. HCRI will serve as a Data Analytic Center for proposals submitted to the ACC's National Cardiovascular Data Registry for research based on data from PINNACLE-AF, the atrial fibrillation platform for PINNACLE. Working in close collaboration with investigators and the ACC, HCRI will conduct data analysis for research projects approved by the ACC.
Medscape (3/25, Busko, 201K) reports that research indicated that “compared with stopping dual antiplatelet therapy (DAPT) at 12 months, extending therapy to 30 months reduced the risk of stent thrombosis and MI but also increased the risk of mild to moderate bleeding in patients who had a coronary stent implanted—whether this followed an initial MI or stable angina.” .